Tech Company Financing Transactions
Superluminal Medicines Funding Round
On 9/9/2024, Superluminal Medicines raised $120 million in Series A investment from RA Capital Management, Catalio Capital Management and Cooley.
Transaction Overview
Company Name
Announced On
9/9/2024
Transaction Type
Venture Equity
Amount
$120,000,000
Round
Series A
Investors
RA Capital Management (Lead Investor) (Andrew Levin)
Proceeds Purpose
The company intends to use the funds to support the progression of its lead program into clinical development and increase the number of small molecule drug discovery programs focused on high-value G protein-coupled receptor (GPCR) targets.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
200 Berkeley St, 18th Floor
Boston, MA 02116
USA
Boston, MA 02116
USA
Phone
Undisclosed
Website
Email Address
Overview
Superluminal Medicines is a generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created. The company's platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Cony D'Cruz
Browse more venture capital transactions:
Prev: 9/9/2024: ArcanaBio venture capital transaction
Next: 9/9/2024: Epsilogen venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs